Recurrent Adult Brain Tumor Clinical Trial
Official title:
Proton Radiation for Low Grade Gliomas
Verified date | December 2020 |
Source | Abramson Cancer Center of the University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the best way to give proton beam radiation therapy and to see how well it works in treating patients with low grade gliomas.
Status | Completed |
Enrollment | 23 |
Est. completion date | February 2014 |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion - Patients with histologically confirmed diagnosis of low grade glioma of the CNS - Patients with WHO grade II; may be symptomatic; including patients who are being followed and have radiographic expression - Patients must have a Karnofsky Performance Status of >= 60 - Patients must be able to provide informed consent - Patients must have adequate bone marrow function: 1. WBC >= 4000/mm^3 2. platelets >= 100,000 mm^3 - Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods etc); Hysterectomy or menopause must be clinically documented Exclusion - Patients who have had prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma) - Patients with the following histologies: gliomatosis cerebrei, WHO III or IV gliomas - Patients who have had any prior Radiation treatment - Patients who have had any chemotherapy administered within 30 days of the planned radiation treatment start date - Pregnant women, women planning to become pregnant and women that are nursing - Patients who are actively being treated on any other therapeutic research study |
Country | Name | City | State |
---|---|---|---|
United States | Abramson Cancer Center of The University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Abramson Cancer Center of the University of Pennsylvania |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility (phase I) | |||
Primary | Acute toxicity as assessed by NCI CTC version 3.0 (phases I and II) | 60 days (phase I) or 90 days (phase II) from completion of radiation therapy | ||
Secondary | Late toxicity as graded according to the RTOG/EORTC late morbidity scoring system (phases I and II) | |||
Secondary | Fatigue as assessed by the Brief Fatigue Inventory (phases I and II) | Pre-radiation, mid-treatment, and post-radiation; at 3, 6, 9, and 12 months post-radiation; and then every 6 months | ||
Secondary | Cumulative total dose to normal brain tissue (phase II) | |||
Secondary | Progression-free survival (phases I and II) | |||
Secondary | Overall survival (phases I and II) | |||
Secondary | Adverse events as assessed by NCI CTCAE version 3.0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Completed |
NCT00045708 -
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03890952 -
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
|
Phase 2 | |
Terminated |
NCT01814813 -
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
|
Phase 2 | |
Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00016328 -
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00006773 -
Bortezomib in Treating Patients With Recurrent Glioma
|
Phase 1 | |
Completed |
NCT01806675 -
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
|
Phase 1/Phase 2 | |
Terminated |
NCT01148966 -
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
|
Phase 1 | |
Completed |
NCT00492089 -
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT01125046 -
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
|
Phase 2 | |
Completed |
NCT01894061 -
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT01644955 -
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Terminated |
NCT01269411 -
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
|
Phase 1 | |
Completed |
NCT00641706 -
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
|
Phase 2 |